Watch NXTC. Know when insiders buy.
One email the day a filing lands. Free.
NXTC
NextCure, Inc.
5.41
−0.03 −0.46%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $24.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$42.7MNET CASH $15.3M52W 1.60 – 14.27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15.1M | −$14.9M | — | -2.80 | −$9.7M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$10.1M | −$9.8M | — | -1.87 | −$13.4M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.8M | −$9.4M | — | -0.81 | −$7.6M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$8.9M | −$8.6M | — | -3.22 | −$6.3M | — | — | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$27.3M | −$26.8M | — | -11.29 | −$22.7M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$11.6M | −$11M | — | -4.70 | −$13M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.5M | −$11.6M | — | -4.97 | −$7M | −$34K | −$6.9M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$12.5M | −$11.5M | — | -4.95 | −$11.5M | $170K | −$11.6M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$16.5M | −$15.4M | — | -6.61 | −$9.8M | $301K | −$10.1M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$18.3M | −$17.1M | — | -0.61 | −$12.6M | $37K | −$12.6M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.8M | −$14.5M | — | -0.52 | −$10.7M | $13K | −$10.7M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$15.6M | −$14.3M | — | -0.51 | −$12.8M | $279K | −$13.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$57.6M | −$55.8M | — | -19.65 | −$49.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$59.7M | −$55.7M | — | -23.88 | −$40.8M | $474K | −$41.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$67.6M | −$62.7M | — | -2.25 | −$53M | $820K | −$53.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$75.9M | −$74.7M | — | -2.69 | −$53.9M | $2.1M | −$56M | — | — |
| FY2021 · to Dec 31 | — | — | −$70.8M | −$69.4M | — | -2.51 | −$57.3M | $2.4M | −$59.6M | — | — |
| FY2020 · to Dec 31 | $22.4M | — | −$41.2M | −$36.6M | -163.6% | -1.33 | −$45M | $7.1M | −$52.1M | — | — |
Every number comes from NextCure, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.